HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jutong Si Selected Research

KN 62

11/2007The retinoic acid receptor/CaMKII interaction: pharmacologic inhibition of CaMKII enhances the differentiation of myeloid leukemia cells.
5/2007KN-62 analogues as potent differentiating agents of HL-60 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jutong Si Research Topics

Disease

4Myeloid Leukemia (Leukemia, Myelocytic)
05/2008 - 05/2007
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
05/2008 - 02/2002
2Acute Promyelocytic Leukemia
11/2007 - 02/2002
2Leukemia
05/2007 - 05/2007
1Neoplasms (Cancer)
12/2010

Drug/Important Bio-Agent (IBA)

3Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
05/2008 - 05/2007
3Calcium-Calmodulin-Dependent Protein KinasesIBA
05/2008 - 05/2007
3Tretinoin (Retinoic Acid)FDA LinkGeneric
11/2007 - 05/2007
3Retinoic Acid Receptors (Retinoic Acid Receptor)IBA
11/2007 - 02/2002
2KN 62IBA
11/2007 - 05/2007
1Glutathione (Reduced Glutathione)IBA
12/2010
1Mitogen-Activated Protein KinasesIBA
05/2008
1beta CateninIBA
05/2008
1Phosphotransferases (Kinase)IBA
05/2008
1Glycogen Synthase KinasesIBA
05/2008
1Glycogen Synthase Kinase 3 betaIBA
05/2008
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
05/2007
1CytokinesIBA
02/2002
1RetinoidsIBA
02/2002
1LigandsIBA
02/2002

Therapy/Procedure

2Therapeutics
12/2010 - 05/2008